4//SEC Filing
BRATTON DOUGLAS K 4
Accession 0000899243-20-033903
CIK 0001714899other
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 4:47 PM ET
Size
18.9 KB
Accession
0000899243-20-033903
Insider Transaction Report
Form 4
BRATTON DOUGLAS K
10% Owner
Transactions
- Sale
Common Stock
2020-12-14$81.13/sh−876$71,068→ 383,411 total(indirect: By Neuro Line Partners, L.P.) - Sale
Common Stock
2020-12-11$80.05/sh−46,799$3,746,442→ 401,236 total(indirect: By Neuro Line Partners, L.P.) - Sale
Common Stock
2020-12-14$80.35/sh−16,949$1,361,774→ 384,287 total(indirect: By Neuro Line Partners, L.P.)
Holdings
- 12,201,634(indirect: By AKDL, L.P.)
Common Stock
Neuro Line Partners LP
10% Owner
Transactions
- Sale
Common Stock
2020-12-14$81.13/sh−876$71,068→ 383,411 total(indirect: By Neuro Line Partners, L.P.) - Sale
Common Stock
2020-12-11$80.05/sh−46,799$3,746,442→ 401,236 total(indirect: By Neuro Line Partners, L.P.) - Sale
Common Stock
2020-12-14$80.35/sh−16,949$1,361,774→ 384,287 total(indirect: By Neuro Line Partners, L.P.)
Holdings
- 12,201,634(indirect: By AKDL, L.P.)
Common Stock
Bratton Capital Management, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-12-14$80.35/sh−16,949$1,361,774→ 384,287 total(indirect: By Neuro Line Partners, L.P.) - Sale
Common Stock
2020-12-14$81.13/sh−876$71,068→ 383,411 total(indirect: By Neuro Line Partners, L.P.) - Sale
Common Stock
2020-12-11$80.05/sh−46,799$3,746,442→ 401,236 total(indirect: By Neuro Line Partners, L.P.)
Holdings
- 12,201,634(indirect: By AKDL, L.P.)
Common Stock
Bratton Capital Inc.
10% Owner
Transactions
- Sale
Common Stock
2020-12-11$80.05/sh−46,799$3,746,442→ 401,236 total(indirect: By Neuro Line Partners, L.P.) - Sale
Common Stock
2020-12-14$80.35/sh−16,949$1,361,774→ 384,287 total(indirect: By Neuro Line Partners, L.P.) - Sale
Common Stock
2020-12-14$81.13/sh−876$71,068→ 383,411 total(indirect: By Neuro Line Partners, L.P.)
Holdings
- 12,201,634(indirect: By AKDL, L.P.)
Common Stock
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.83 to $80.31, inclusive. The reporting persons undertake to provide to Denali Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4) and (5) to this Form 4.
- [F2]These shares of common stock of the Issuer are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.
- [F3](Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.10 to $80.99, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.115 to $81.18, inclusive.
- [F6]These shares of common stock of the Issuer are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.
- [F7](Continued from Footnote 6) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.
Issuer
Denali Therapeutics Inc.
CIK 0001714899
Entity typeother
Related Parties
1- filerCIK 0001281933
Filing Metadata
- Form type
- 4
- Filed
- Dec 14, 7:00 PM ET
- Accepted
- Dec 15, 4:47 PM ET
- Size
- 18.9 KB